Literature DB >> 6939932

Intralymphatic administration of liposome-encapsulated drugs to mice: possibility for suppression of the growth of tumor metastases in the lymph nodes.

V I Kaledin, N A Matienko, V P Nikolin, Y V Gruntenko, V G Budker.   

Abstract

The antimetastatic effects of two drugs, cis-diamminedichloroplatinum(II) (DDP) and hydrocortisone (liposome-incorporated or free), were studied. The experimental models were regional and distant metastases of hepatoma A and pulmonary adenocarcinoma, which were transplanted into the footpads of A/He mice. Liposomes were prepared from phosphatidylcholine by sonic dispersion. DDP and hydrocortisone were injected sc into the region of the plantar aponeurosis of the foot with the primary tumor. This administration route was considered to be equivalent to the intralymphatic route. Evidence indicated that only liposome-incorporated DDP and hydrocortisone decreased significantly the frequency and growth rate of tumor metastases in the regional lymph nodes. The effect observed was not due to the direct action of the drugs on the primary tumors. When nonencapsulated, these drugs were ineffective. Both liposome-encapsulated and free DDP did not affect distant metastases of pulmonary adenocarcinoma. The intralymphatic administration of liposome-encapsulated antitumor agents is suggested as a method for the prophylactic treatment of tumor metastases in the lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6939932

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration - effect of lipid composition.

Authors:  K Hirano; C A Hunt; A Strubbe; R D Macgregor
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

2.  Folate-PEG-CKK(2)-DTPA, A Potential Carrier for Lymph-Metastasized Tumor Targeting.

Authors:  Bing Gu; Cao Xie; Jianhua Zhu; Wei He; Weiyue Lu
Journal:  Pharm Res       Date:  2010-03-11       Impact factor: 4.200

3.  Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Authors:  P A Steerenberg; G Storm; G de Groot; A Claessen; J J Bergers; M A Franken; Q G van Hoesel; K L Wubs; W H de Jong
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes.

Authors:  S Kim; D J Kim; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 5.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 6.  Lymphatic metastasis.

Authors:  I Carr
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

7.  Lymphatic metastasis; lymphangiochemotherapy of mammary cancer: ascitic form of rat mammary adenocarcinoma 13762.

Authors:  J Carr; B Dreher; I Carr
Journal:  Clin Exp Metastasis       Date:  1983 Jan-Mar       Impact factor: 5.150

8.  Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.

Authors:  J Bubeník; J Jezek; M Zaoral; J Hofmann; Y V Gruntenko; J G Osipov; A G Zolotareva; T E Vakhrusheva; V G Budker
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids.

Authors:  Yuval Avnir; Keren Turjeman; Deborah Tulchinsky; Alex Sigal; Pablo Kizelsztein; Dina Tzemach; Alberto Gabizon; Yechezkel Barenholz
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.